Secondary hormonal manipulations in prostate cancer

Charles J. Ryan, Eric J. Small

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Virtually all patients treated with androgen deprivation eventually develop progressive clinical or biochemical disease despite this therapy. Despite low levels of androgen, the androgen receptor remains active, making secondary hormonal therapies a reasonable clinical approach. Considerations for such patients include antiandrogen withdrawal, sequential use of antiandrogens, adrenal cortex inhibitors, and estrogenic compounds. Collectively, the modest activity of these therapies challenges the notion that advancing prostate cancer will uniformly become "hormone refractory."

Original languageEnglish (US)
Pages (from-to)228-233
Number of pages6
JournalCurrent oncology reports
Issue number3
StatePublished - May 2005
Externally publishedYes


Dive into the research topics of 'Secondary hormonal manipulations in prostate cancer'. Together they form a unique fingerprint.

Cite this